Display options
Cite
Suzuki K, Nishi K, Takabuchi S, et al. Differential roles of prostaglandin E-type receptors in activation of hypoxia-inducible factor 1 by prostaglandin E1 in vascular-derived cells under non-hypoxic conditions. PeerJ. 2013;1:e220doi: 10.7717/peerj.220.
Suzuki, K., Nishi, K., Takabuchi, S., Kai, S., Matsuyama, T., Kurosawa, S., Adachi, T., Maruyama, T., Fukuda, K., & Hirota, K. (2013). Differential roles of prostaglandin E-type receptors in activation of hypoxia-inducible factor 1 by prostaglandin E1 in vascular-derived cells under non-hypoxic conditions. PeerJ, 1e220. https://doi.org/10.7717/peerj.220
Suzuki, Kengo, et al. "Differential roles of prostaglandin E-type receptors in activation of hypoxia-inducible factor 1 by prostaglandin E1 in vascular-derived cells under non-hypoxic conditions." PeerJ vol. 1 (2013): e220. doi: https://doi.org/10.7717/peerj.220
Suzuki K, Nishi K, Takabuchi S, Kai S, Matsuyama T, Kurosawa S, Adachi T, Maruyama T, Fukuda K, Hirota K. Differential roles of prostaglandin E-type receptors in activation of hypoxia-inducible factor 1 by prostaglandin E1 in vascular-derived cells under non-hypoxic conditions. PeerJ. 2013 Nov 28;1:e220. doi: 10.7717/peerj.220. eCollection 2013. PMID: 24349900; PMCID: PMC3845874.
Copy Download .nbib Format: NLM
Share it on

PeerJ. 2013 Nov 28;1:e220. doi: 10.7717/peerj.220. eCollection 2013.

Differential roles of prostaglandin E-type receptors in activation of hypoxia-inducible factor 1 by prostaglandin E1 in vascular-derived cells under non-hypoxic conditions.

PeerJ

Kengo Suzuki, Kenichiro Nishi, Satoshi Takabuchi, Shinichi Kai, Tomonori Matsuyama, Shin Kurosawa, Takehiko Adachi, Takayuki Maruyama, Kazuhiko Fukuda, Kiichi Hirota

Affiliations

  1. Department of Anesthesia, Kyoto University Hospital , Kyoto , Japan ; Department of Anesthesiology, Tohoku University Hospital , Sendai , Japan.
  2. Department of Anesthesiology, Kansai Medical University , Hirakata, Osaka , Japan.
  3. Department of Anesthesia, Kyoto University Hospital , Kyoto , Japan.
  4. Department of Anesthesiology, Tohoku University Hospital , Sendai , Japan.
  5. Department of Anesthesia, Tazuke Kofukai Medical Research Institute Kitano Hospital , Osaka , Japan.
  6. Minase Research Institutes, Research Headquarters, Ono Pharmaceutical , Osaka , Japan.

PMID: 24349900 PMCID: PMC3845874 DOI: 10.7717/peerj.220

Abstract

Prostaglandin E1 (PGE1), known pharmaceutically as alprostadil, has vasodilatory properties and is used widely in various clinical settings. In addition to acute vasodilatory properties, PGE1 may exert beneficial effects by altering protein expression of vascular cells. PGE1 is reported to be a potent stimulator of angiogenesis via upregulation of VEGF expression, which is under the control of the transcription factor hypoxia-inducible factor 1 (HIF-1). However, the molecular mechanisms behind the phenomenon are largely unknown. In the present study, we investigated the mechanism by which PGE1 induces HIF-1 activation and VEGF gene expression in human aortic smooth muscle cells (HASMCs) and human umbilical vein endothelial cells (HUVECs), both vascular-derived cells. HUVECs and HASMCs were treated with PGE1 at clinically relevant concentrations under 20% O2 conditions and HIF-1 protein expression was investigated. Expression of HIF- 1α protein and the HIF-1-downstream genes were low under 20% O2 conditions and increased in response to PGE1 treatment in both HUVECs and HASMCs in a dose- and time-dependent manner under 20% O2 conditions as comparable to exposure to 1% O2 conditions. Studies using EP-receptor-specific agonists and antagonists revealed that EP1 and EP3 are critical to PGE1-induced HIF-1 activation. In vitro vascular permeability assays using HUVECs indicated that PGE1 increased vascular permeability in HUVECs. Thus, we demonstrate that PGE1 induces HIF- 1α protein expression and HIF-1 activation under non-hypoxic conditions and also provide evidence that the activity of multiple signal transduction pathways downstream of EP1 and EP3 receptors is required for HIF-1 activation.

Keywords: Angiogenesis; EP receptor; Human endothelial cells; Human smooth muscle cells; Hypoxia-inducible factor; Prostaglandin E1; VEGF

References

  1. Biomed Pharmacother. 2003 May-Jun;57(3-4):173-8 - PubMed
  2. FEBS Lett. 2004 Nov 19;577(3):434-8 - PubMed
  3. Arq Gastroenterol. 2009 Oct-Dec;46(4):333-40 - PubMed
  4. J Biol Chem. 2007 Apr 20;282(16):11613-7 - PubMed
  5. Mol Cell Biol. 2001 Jun;21(12):3995-4004 - PubMed
  6. Biochem Biophys Res Commun. 2005 Dec 9;338(1):610-6 - PubMed
  7. J Cell Physiol. 2006 Apr;207(1):261-70 - PubMed
  8. J Exp Med. 2003 Jan 20;197(2):221-32 - PubMed
  9. Am J Physiol Regul Integr Comp Physiol. 2010 Mar;298(3):R661-71 - PubMed
  10. Am J Physiol Cell Physiol. 2006 Jul;291(1):C104-13 - PubMed
  11. Int J Biochem Cell Biol. 2005 Mar;37(3):535-40 - PubMed
  12. Nat Rev Immunol. 2009 Sep;9(9):609-17 - PubMed
  13. Crit Rev Oncol Hematol. 2006 Jul;59(1):15-26 - PubMed
  14. Br J Pharmacol. 2003 Jan;138(2):377-85 - PubMed
  15. Biochem J. 2008 Apr 1;411(1):97-105 - PubMed
  16. Circ Res. 2001 Jul 6;89(1):47-54 - PubMed
  17. J Pharmacol Sci. 2013;122(2):158-61 - PubMed
  18. PLoS One. 2008 May 21;3(5):e2215 - PubMed
  19. Eur J Pharmacol. 2009 Mar 15;606(1-3):130-6 - PubMed
  20. PLoS One. 2011;6(12):e29378 - PubMed
  21. Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5510-4 - PubMed
  22. Biol Chem. 2006 Oct-Nov;387(10-11):1337-46 - PubMed
  23. Cancer Res. 2003 May 1;63(9):2330-4 - PubMed
  24. J Biol Chem. 2004 Jan 23;279(4):2550-8 - PubMed
  25. Pharmacol Rev. 1994 Jun;46(2):205-29 - PubMed
  26. Biochem Biophys Res Commun. 2005 Dec 9;338(1):617-26 - PubMed
  27. Mol Pharmacol. 2010 Jun;77(6):1025-36 - PubMed
  28. Br J Clin Pharmacol. 1995 Sep;40(3):273-6 - PubMed
  29. Endocrinology. 2000 Apr;141(4):1554-9 - PubMed
  30. Prostaglandins Other Lipid Mediat. 2009 Nov;90(1-2):31-6 - PubMed
  31. J Mol Cell Cardiol. 2004 Apr;36(4):539-46 - PubMed
  32. Eur J Pharmacol. 2011 Sep 30;667(1-3):144-52 - PubMed
  33. J Biol Chem. 2002 Oct 11;277(41):38205-11 - PubMed
  34. J Biol Chem. 2004 Oct 1;279(40):41521-8 - PubMed
  35. Physiol Rev. 1999 Oct;79(4):1193-226 - PubMed
  36. Am J Physiol Heart Circ Physiol. 2005 Nov;289(5):H2066-72 - PubMed

Publication Types